A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

被引：0
|
作者：
Maureen Watt
Charles McCrea
Sukhvinder Johal
John Posnett
Jameel Nazir
机构：
[1] Astellas EMEA,
[2] PAREXEL Access Consulting,undefined
[3] Astellas Pharma Europe Ltd.,undefined
来源：
Infection | 2016年 / 44卷
关键词：
Cost-effectiveness; Budget impact; Fidaxomicin; Vancomycin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 606
页数：7
相关论文
共 50 条
  • [1] A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
    Watt, Maureen
    McCrea, Charles
    Johal, Sukhvinder
    Posnett, John
    Nazir, Jameel
    INFECTION, 2016, 44 (05) : 599 - 606
  • [2] A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF FIDAXOMICIN FOR TREATING CLOSTRIDIUM DIFFICILE PATIENTS IN GERMANY
    Watt, M.
    McCrea, C.
    Johal, S.
    Posnett, J.
    Nazir, J.
    VALUE IN HEALTH, 2015, 18 (03) : A233 - A233
  • [3] COST-EFFECTIVENESS OF FIDAXOMICIN FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN SWEDEN
    Van Engen, A.
    Lie, X.
    Noren, T.
    Nordling, S.
    Norgaard, K.
    VALUE IN HEALTH, 2014, 17 (07) : A673 - A674
  • [4] Experience With Fidaxomicin as First-Line Treatment for C. difficile Infection (CDI): Clinical Outcomes and Cost-Effectiveness
    Planche, Tim
    Whitney, Laura
    Ahmad, Attiq
    Nesnas, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S678 - S678
  • [5] COST-EFFECTIVENESS ANALYSIS OF FIDAXOMICIN FOR CLOSTRIDIUM DIFFICILE INFECTION IN JAPAN
    Okumura, H.
    Ueyama, M.
    Shoji, S.
    English, M.
    VALUE IN HEALTH, 2019, 22 : S200 - S200
  • [6] Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
    Nathwani, Dilip
    Cornely, Oliver A.
    Van Engen, Anke K.
    Odufowora-Sita, Olatunji
    Retsa, Peny
    Odeyemi, Isaac A. O.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (11) : 2901 - 2912
  • [7] COST-EFFECTIVENESS OF FIDAXOMICIN THERAPY FOR CLOSTRIDIUM DIFFICILE INFECTION IN HUNGARY
    Brodszky, V
    Strbak, B.
    Baji, P.
    Pentek, M.
    Gulacsi, L.
    VALUE IN HEALTH, 2014, 17 (07) : A675 - A675
  • [8] Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan
    Okumura, Hiroyuki
    Ueyama, Maki
    Shoji, Shingo
    English, Marci
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (06) : 611 - 618
  • [9] Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment
    Simon, Matthew S.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (04)
  • [10] COST-EFFECTIVENESS OF FIDAXOMICIN VERSUS VANCOMYCIN AND METRONIDAZOLE IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION IN SPAIN
    Watt, M.
    de Nigris, E.
    McCrea, C.
    VALUE IN HEALTH, 2017, 20 (09) : A784 - A784
12345